1. >
  2. Investors
  3. >
  4. Regulated Information
  5. >
  6. Press Releases – Reg...

PRESS RELEASES

Found 284 Results
Page 26 of 29

Definitive Merger Plan between BioAlliance Pharma and Topotarget – Combined Entity to be named Onxeo


 DEFINITIVE MERGER PLAN BETWEEN BIOALLIANCE PHARMA AND TOPOTARGET COMBINED ENTITY TO BE NAMED ONXEO  — Onxeo expected to have a […]

Tags:

05/21/2014


Livatag® receives Fast Track Designation from the FDA for the treatment of primary liver cancer


BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, […]

05/19/2014



Quarterly information as of March 31, 2014


BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, […]

Tags:

04/30/2014


BioAlliance Pharma Publishes its first Shareholder Newsletter


BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, […]

Tags:

04/29/2014


BioAlliance Pharma and Topotarget enter into merger agreement to create a leading orphan oncology company


— Combined company expected to have increased scale and a highly complementary pipeline of late-stage products addressing significant unmet medical […]

Tags:

04/16/2014


BioAlliance Pharma announces a new positive DSMB recommendation to continue its Phase III clinical trial with Livatag® in primary liver cancer


BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, […]

04/14/2014


Publication of the 2013 Registration Document


BioAlliance Pharma SA (Euronext Paris – BIO), Société d’innovation spécialisée dans le développement de médicaments visant des pathologies orphelines en […]

Tags:

04/08/2014


BioAlliance Pharma Announces Shareholders’ Meeting and Approval of all resolutions


BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, […]

Tags:


BioAlliance Pharma signs a new licensing agreement with Daewoong Pharmaceutical Co., Ltd. for Sitavig®’s commercialization in South Korea


BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, […]

Tags:

04/02/2014


Page 26 of 29